{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T08:32:31Z","timestamp":1790152351869,"version":"4.0.1"},"reference-count":31,"publisher":"Cambridge University Press (CUP)","license":[{"start":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T00:00:00Z","timestamp":1557964800000},"content-version":"unspecified","delay-in-days":135,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epidemiol. Infect."],"published-print":{"date-parts":[[2019]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We present a model to optimise a vaccination campaign aiming to prevent or to curb a Zika virus outbreak. We show that the optimum vaccination strategy to reduce the number of cases by a mass vaccination campaign should start when the <jats:italic>Aedes<\/jats:italic> mosquitoes' density reaches the threshold of 1.5 mosquitoes per humans, the moment the reproduction number crosses one. The maximum time it is advisable to wait for the introduction of a vaccination campaign is when the first ZIKV case is identified, although this would not be as effective to minimise the number of infections as when the mosquitoes' density crosses the critical threshold. This suboptimum strategy, however, would still curb the outbreak. In both cases, the catch up strategy should aim to vaccinate at least 25% of the target population during a concentrated effort of 1 month immediately after identifying the threshold. This is the time taken to accumulate the herd immunity threshold of 56.5%. These calculations were done based on theoretical assumptions that vaccine implementation would be feasible within a very short time frame.<\/jats:p>","DOI":"10.1017\/s0950268819000712","type":"journal-article","created":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T05:15:51Z","timestamp":1557983751000},"source":"Crossref","is-referenced-by-count":9,"title":["Modelling an optimum vaccination strategy against ZIKA virus for outbreak use"],"prefix":"10.1017","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7200-2916","authenticated-orcid":false,"given":"Eduardo","family":"Massad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Antonio Bezerra","family":"Coutinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelies","family":"Wilder-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2019,5,16]]},"reference":[{"key":"S0950268819000712_ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s11538-014-9939-5"},{"key":"S0950268819000712_ref26","first-page":"e01390","article-title":"High Zika virus seroprevalence in salvador, Northeastern Brazil limits the potential for further outbreaks","volume":"8","author":"Martins Netto","year":"2017","journal-title":"MBio"},{"key":"S0950268819000712_ref25","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268817000358"},{"key":"S0950268819000712_ref22","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268818001334"},{"key":"S0950268819000712_ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.idm.2017.12.001"},{"key":"S0950268819000712_ref20","unstructured":"WHO (2018b) Zika Vaccine Development Technology Roadmap. Available at https:\/\/www.who.int\/immunization\/research\/development\/Zika_Vaccine_Development_Technology_Roadmap_final_2018.pdf?ua=1 (Accessed 16 October 2018)."},{"key":"S0950268819000712_ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1158-8"},{"key":"S0950268819000712_ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708120"},{"key":"S0950268819000712_ref15","unstructured":"WHO (2018a) Vaccine Pipeline Tracker. Available from: https:\/\/docs.google.com\/spreadsheets\/d\/19otvINcayJURCMg76xWO4KvuyedYbMZDcXqbyJGdcZM\/pubhtml# (Accessed 20 August 2018)."},{"key":"S0950268819000712_ref13","first-page":"250","article-title":"Assessing seasonal risks for the introduction and mosquito-borne spread of Zika virus in Europe","volume":"9","author":"Rocklov","year":"2016","journal-title":"EBio Medicine"},{"key":"S0950268819000712_ref12","doi-asserted-by":"publisher","DOI":"10.3402\/gha.v9.31669"},{"key":"S0950268819000712_ref7","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taw066"},{"key":"S0950268819000712_ref5","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taw059"},{"key":"S0950268819000712_ref3","doi-asserted-by":"publisher","DOI":"10.1080\/16549716.2017.1398485"},{"key":"S0950268819000712_ref2","unstructured":"WHO (2016) Situation Report. Zika Virus Microcephaly Guillin-Barr\u00e9 Syndrome. Available at http:\/\/origin.searo.who.int\/bhutan\/who-zika-28-7-16.pdf. Accessed 10 October 2018."},{"key":"S0950268819000712_ref1","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268817001200"},{"key":"S0950268819000712_ref28","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1989.40.571"},{"key":"S0950268819000712_ref24","first-page":"229","article-title":"Sensitivity and uncertainty analysis of complex models of disease transmission: an HIV model, as an example","volume":"62","author":"Blower","year":"1994","journal-title":"International Statistical Review\/Revue Internationale De Statistique"},{"key":"S0950268819000712_ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1067-x"},{"key":"S0950268819000712_ref10","unstructured":"Pan American Health Organization (PAHO)\/World Health Organization (WHO) (2016). Zika Epidemiological Update, 15 December 2016. PAHO\/WHO."},{"key":"S0950268819000712_ref31","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy073"},{"key":"S0950268819000712_ref8","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/tay022"},{"key":"S0950268819000712_ref4","doi-asserted-by":"publisher","DOI":"10.1111\/jtm.12208"},{"key":"S0950268819000712_ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.09.020"},{"key":"S0950268819000712_ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22590-5"},{"key":"S0950268819000712_ref9","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/tay044"},{"key":"S0950268819000712_ref30","doi-asserted-by":"publisher","DOI":"10.1590\/S0074-02762008000600004"},{"key":"S0950268819000712_ref23","volume-title":"Bootstrap Methods: A Guide for Practitioners and Researchers","author":"Chernick","year":"2008"},{"key":"S0950268819000712_ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2016.09.001"},{"key":"S0950268819000712_ref19","unstructured":"The Pharmaceutical Journal , February 2018, Vol 300, No 7910, online DOI: 10.1211\/PJ.2018.20204340 https:\/\/www.pharmaceutical-journal.com\/news-and-analysis\/features\/zika-vaccine-development-two-years-on-from-the-outbreak\/20204340.article?firstPass=false (Accessed 5 September 2018)."},{"key":"S0950268819000712_ref6","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/tav011"}],"container-title":["Epidemiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0950268819000712","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T17:53:20Z","timestamp":1559930000000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0950268819000712\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":31,"alternative-id":["S0950268819000712"],"URL":"https:\/\/doi.org\/10.1017\/s0950268819000712","relation":{},"ISSN":["0950-2688","1469-4409"],"issn-type":[{"value":"0950-2688","type":"print"},{"value":"1469-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]},"article-number":"e196"}}